CABLIVI

This brand name is authorized in Austria, Brazil, Canada, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, Poland, Romania, United Kingdom, United States

Active ingredients

The drug CABLIVI contains one active pharmaceutical ingredient (API):

1 Caplacizumab UNII 2R27AB6766 - CAPLACIZUMAB

Caplacizumab is a humanised bivalent Nanobody that consists of two identical humanised building blocks (PMP12A2hum1), genetically linked by a three-alanine linker, targeting the A1-domain of von Willebrand factor and inhibiting the interaction between von Willebrand factor and platelets. As such, caplacizumab prevents the ultralarge von Willebrand factor-mediated platelet adhesion, which is characteristic of aTTP. It also affects the disposition of von Willebrand factor, leading to transient reductions of total von Willebrand factor antigen levels and to concomitant reduction of factor VIII:C levels during treatment. Read about Caplacizumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CABLIVI Powder and solvent for solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
B01AX07		B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AX Other antithrombotic agents
Discover more medicines within B01AX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 576721090096401
Country: CA	Health Products and Food Branch	Identifier(s): 02496194
Country: EE	Ravimiamet	Identifier(s): 1779015, 1802517
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1181305001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 067273
Country: FR	Base de données publique des médicaments	Identifier(s): 64183564
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 377580
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8499
Country: JP	医薬品医療機器総合機構	Identifier(s): 3399415D1027
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1086199, 1086755, 1087361
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 197416
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100410686
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65588001, W65588002, W65588003
Country: US	FDA, National Drug Code	Identifier(s): 58468-0225, 58468-0227, 58468-0229